JP2010540539A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540539A5 JP2010540539A5 JP2010527021A JP2010527021A JP2010540539A5 JP 2010540539 A5 JP2010540539 A5 JP 2010540539A5 JP 2010527021 A JP2010527021 A JP 2010527021A JP 2010527021 A JP2010527021 A JP 2010527021A JP 2010540539 A5 JP2010540539 A5 JP 2010540539A5
- Authority
- JP
- Japan
- Prior art keywords
- aerosol
- dose
- area
- azli
- inhalation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000443 aerosol Substances 0.000 claims description 400
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 274
- 238000011282 treatment Methods 0.000 claims description 204
- 208000024891 symptom Diseases 0.000 claims description 169
- 239000011780 sodium chloride Substances 0.000 claims description 152
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 140
- 239000006199 nebulizer Substances 0.000 claims description 123
- 229960003644 aztreonam Drugs 0.000 claims description 113
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims description 112
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims description 110
- 239000002245 particle Substances 0.000 claims description 103
- 230000000241 respiratory effect Effects 0.000 claims description 103
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 77
- KPPBAEVZLDHCOK-JHBYREIPSA-N (2s,3s)-3-[[(2z)-2-(2-azaniumyl-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonate;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 KPPBAEVZLDHCOK-JHBYREIPSA-N 0.000 claims description 74
- 229950010471 aztreonam lysine Drugs 0.000 claims description 74
- 239000000843 powder Substances 0.000 claims description 68
- 235000005686 eating Nutrition 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 40
- 229940079593 drug Drugs 0.000 claims description 39
- 210000004072 lung Anatomy 0.000 claims description 37
- 230000036541 health Effects 0.000 claims description 33
- 230000002685 pulmonary effect Effects 0.000 claims description 23
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 20
- 238000009472 formulation Methods 0.000 claims description 16
- 230000029087 digestion Effects 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 3
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 1
- 229960002626 clarithromycin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 100
- 239000000902 placebo Substances 0.000 description 92
- 229940068196 placebo Drugs 0.000 description 91
- 230000008859 change Effects 0.000 description 53
- 206010036790 Productive cough Diseases 0.000 description 33
- 208000024794 sputum Diseases 0.000 description 33
- 210000003802 sputum Anatomy 0.000 description 33
- 208000034332 Body integrity dysphoria Diseases 0.000 description 32
- 208000019693 Lung disease Diseases 0.000 description 32
- 230000004044 response Effects 0.000 description 31
- 230000006872 improvement Effects 0.000 description 30
- 239000003242 anti bacterial agent Substances 0.000 description 26
- 229940088710 antibiotic agent Drugs 0.000 description 26
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 25
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 24
- 230000007423 decrease Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 239000004472 Lysine Substances 0.000 description 22
- 229960003646 lysine Drugs 0.000 description 22
- 238000002560 therapeutic procedure Methods 0.000 description 22
- 229960000707 tobramycin Drugs 0.000 description 22
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 235000018977 lysine Nutrition 0.000 description 20
- 201000010099 disease Diseases 0.000 description 18
- 238000012216 screening Methods 0.000 description 17
- 230000003247 decreasing effect Effects 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 15
- 230000004199 lung function Effects 0.000 description 14
- 235000012054 meals Nutrition 0.000 description 14
- 210000002345 respiratory system Anatomy 0.000 description 14
- 230000003115 biocidal effect Effects 0.000 description 13
- 210000000038 chest Anatomy 0.000 description 12
- 229940041682 inhalant solution Drugs 0.000 description 12
- 206010057190 Respiratory tract infections Diseases 0.000 description 10
- 230000002411 adverse Effects 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 9
- 230000009467 reduction Effects 0.000 description 8
- 208000032536 Pseudomonas Infections Diseases 0.000 description 7
- 229960004099 azithromycin Drugs 0.000 description 7
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 230000001079 digestive effect Effects 0.000 description 7
- 230000008447 perception Effects 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 206010063659 Aversion Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007012 clinical effect Effects 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- HZRUTVAFDWTKGD-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;hydrate Chemical compound O.NCCCC[C@H](N)C(O)=O HZRUTVAFDWTKGD-JEDNCBNOSA-N 0.000 description 4
- 102100032341 PCNA-interacting partner Human genes 0.000 description 4
- 101710196737 PCNA-interacting partner Proteins 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 108010067396 dornase alfa Proteins 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000008433 psychological processes and functions Effects 0.000 description 4
- 229940127211 short-acting beta 2 agonist Drugs 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 238000012387 aerosolization Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 239000000168 bronchodilator agent Substances 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000008376 long-term health Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 230000008518 non respiratory effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000013125 spirometry Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 229940035289 tobi Drugs 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 241001673062 Achromobacter xylosoxidans Species 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 241000589513 Burkholderia cepacia Species 0.000 description 2
- 108010078777 Colistin Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 235000019766 L-Lysine Nutrition 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008369 airway response Effects 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000007883 bronchodilation Effects 0.000 description 2
- 229960003346 colistin Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000035611 feeding Effects 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229960002306 lysine monohydrate Drugs 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 2
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 229960004017 salmeterol Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010061822 Drug intolerance Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101150034459 Parpbp gene Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010052251 Respiratory tract congestion Diseases 0.000 description 1
- 206010041101 Small intestinal obstruction Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000244 anti-pseudomonal effect Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 229960000533 dornase alfa Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000013123 lung function test Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 206010045458 umbilical hernia Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99707207P | 2007-10-01 | 2007-10-01 | |
| US99707107P | 2007-10-01 | 2007-10-01 | |
| PCT/US2008/076431 WO2009045706A1 (en) | 2007-10-01 | 2008-09-15 | Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of life in lung diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010540539A JP2010540539A (ja) | 2010-12-24 |
| JP2010540539A5 true JP2010540539A5 (enExample) | 2011-11-04 |
Family
ID=40032482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010527021A Pending JP2010540539A (ja) | 2007-10-01 | 2008-09-15 | 肺疾患の健康関連クオリティオブライフの欠損を処置するための吸入性アズトレオナムリジン |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7973029B2 (enExample) |
| EP (1) | EP2200608A1 (enExample) |
| JP (1) | JP2010540539A (enExample) |
| KR (1) | KR20100093037A (enExample) |
| CN (1) | CN101951906A (enExample) |
| AR (1) | AR068514A1 (enExample) |
| AU (1) | AU2008307268A1 (enExample) |
| BR (1) | BRPI0817636A2 (enExample) |
| CA (1) | CA2701118A1 (enExample) |
| EA (1) | EA201070336A1 (enExample) |
| IL (1) | IL204593A0 (enExample) |
| MX (1) | MX2010003618A (enExample) |
| NZ (1) | NZ584269A (enExample) |
| TW (1) | TW200927193A (enExample) |
| WO (1) | WO2009045706A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214364B2 (en) | 2000-12-27 | 2007-05-08 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
| DK2301524T3 (da) | 2000-12-27 | 2013-07-15 | Gilead Sciences Inc | Inhalerbar aztreonam uden arginin til behandling og forebyggelse af bakterielle lungeinfektioner |
| CN104784159A (zh) * | 2015-04-15 | 2015-07-22 | 苏州惠仁生物科技有限公司 | 氨曲南粉雾剂的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5152456A (en) | 1989-12-12 | 1992-10-06 | Bespak, Plc | Dispensing apparatus having a perforate outlet member and a vibrating device |
| EP0615470B1 (en) | 1991-12-04 | 1995-12-13 | The Technology Partnership Public Limited Company | Fluid droplet production apparatus and method |
| DE19953317C1 (de) | 1999-11-05 | 2001-02-01 | Pari Gmbh | Inhalationsvernebler |
| US6962151B1 (en) | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
| US7214364B2 (en) | 2000-12-27 | 2007-05-08 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
| US7138419B2 (en) * | 2000-12-27 | 2006-11-21 | Corus Pharma, Inc. | Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate |
| DK2301524T3 (da) | 2000-12-27 | 2013-07-15 | Gilead Sciences Inc | Inhalerbar aztreonam uden arginin til behandling og forebyggelse af bakterielle lungeinfektioner |
| DE10102846B4 (de) | 2001-01-23 | 2012-04-12 | Pari Pharma Gmbh | Aerosolgenerator |
-
2008
- 2008-09-15 WO PCT/US2008/076431 patent/WO2009045706A1/en not_active Ceased
- 2008-09-15 KR KR1020107009839A patent/KR20100093037A/ko not_active Withdrawn
- 2008-09-15 NZ NZ584269A patent/NZ584269A/en not_active IP Right Cessation
- 2008-09-15 MX MX2010003618A patent/MX2010003618A/es not_active Application Discontinuation
- 2008-09-15 BR BRPI0817636A patent/BRPI0817636A2/pt not_active IP Right Cessation
- 2008-09-15 AU AU2008307268A patent/AU2008307268A1/en not_active Abandoned
- 2008-09-15 JP JP2010527021A patent/JP2010540539A/ja active Pending
- 2008-09-15 EP EP08836327A patent/EP2200608A1/en not_active Withdrawn
- 2008-09-15 CN CN2008801170106A patent/CN101951906A/zh active Pending
- 2008-09-15 US US12/210,965 patent/US7973029B2/en not_active Expired - Fee Related
- 2008-09-15 EA EA201070336A patent/EA201070336A1/ru unknown
- 2008-09-15 TW TW097135359A patent/TW200927193A/zh unknown
- 2008-09-15 CA CA2701118A patent/CA2701118A1/en not_active Abandoned
- 2008-09-15 AR ARP080104006A patent/AR068514A1/es not_active Application Discontinuation
-
2010
- 2010-03-18 IL IL204593A patent/IL204593A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Retsch-Bogart et al. | Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis | |
| EP1765288B1 (en) | Tobramycin formualtions for treatment of endobronchial infections | |
| Eisenberg et al. | A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems | |
| Westerman et al. | Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study | |
| Alothman et al. | Bronchial constriction and inhaled colistin in cystic fibrosis | |
| Campbell et al. | Use of aerosolized antibiotics in patients with cystic fibrosis | |
| VanDevanter et al. | Tobramycin administered by the TOBI® Podhaler® for persons with cystic fibrosis: a review | |
| Elborn et al. | Bronchiectasis and inhaled tobramycin: a literature review | |
| Chuchalin et al. | Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements | |
| Shrewsbury et al. | Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma | |
| JP2010540539A (ja) | 肺疾患の健康関連クオリティオブライフの欠損を処置するための吸入性アズトレオナムリジン | |
| Wilson et al. | Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better?: A multi‐center, randomized crossover trial | |
| Witt et al. | Dornase alfa: a new option in the management of cystic fibrosis | |
| US20240342239A1 (en) | Treatment of non-cystic fibrosis bronchiectasis | |
| US12178841B2 (en) | Treatment of non-cystic fibrosis bronchiectasis | |
| Suri | A cross-over comparative study of hypertonic saline, alternate and daily rhDNase in children with cystic fibrosis | |
| EA052469B1 (ru) | Лечение некистозных фиброзных (немуковисцидозных) бронхоэктазов | |
| Renee Crowther Labiris et al. | Dry Powder versus Intravenous and Nebulized Gentamicin in Cystic Fibrosis and Bronchiectasis: A Pilot Study | |
| Casale et al. | Long-term safety of flunisolide hydrofluoroalkane metered-dose inhaler in adults and adolescents with asthma | |
| Ibrahim et al. | Inhaled Therapy for Other Respiratory Diseases: Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis | |
| JP2024525752A (ja) | 呼吸器症状の処置 | |
| WO2003101390A2 (en) | Endobronchial delivery of antibiotic in individuals with impaired lung tissue or lung function |